Therapeutic Window for IV Alteplase in Acute Ischemic Stroke
Intravenous alteplase should be administered within 4.5 hours of acute ischemic stroke symptom onset, with the strongest evidence supporting treatment within 3 hours, and treatment should be initiated as rapidly as possible since benefit is time-dependent.
Standard Time Windows
The 2018 AHA/ASA Guidelines establish clear Class I recommendations for two distinct time windows 1:
0-3 Hour Window (Class I, LOE A)
- IV alteplase (0.9 mg/kg, maximum 90 mg) is strongly recommended for eligible patients within 3 hours of symptom onset or last known well
- This window has the strongest evidence base from multiple RCTs
- Applies to all ages (including >80 years) and all stroke severities
- The benefit is most robust in this early window
3-4.5 Hour Window (Class I, LOE B-R)
- IV alteplase is also recommended for selected patients between 3-4.5 hours
- Based primarily on the ECASS-III trial and pooled analyses 1
- Additional exclusion criteria apply in this extended window:
- Age >80 years
- Combined history of diabetes mellitus AND prior stroke
- NIHSS score >25
- Oral anticoagulant use (regardless of INR)
- Imaging showing >1/3 MCA territory involvement
However, the guidelines note these ECASS-III exclusion criteria may not be justified in practice based on subsequent real-world data 1.
Critical Time-Dependency Principle
Every minute matters - the guidelines emphasize that treatment benefit declines steeply with longer time to treatment 1. The median admission-to-treatment time should be 65 minutes or less 2. Treatment should be initiated as quickly as possible within the approved time frames (Class I, LOE A) 1.
Beyond 4.5 Hours: Emerging Evidence
While the standard therapeutic window remains 4.5 hours, recent research suggests potential benefit in highly selected patients beyond this timeframe:
- Wake-up strokes with DWI-FLAIR mismatch may benefit from treatment when last known well was >4.5 hours ago 3
- Recent meta-analyses show improved functional outcomes (RR 1.34 for favorable mRS) when alteplase is given beyond 4.5 hours in imaging-selected patients, though with increased symptomatic ICH risk (RR 4.67) 4, 5, 6
- This extended window approach is NOT part of standard FDA-approved labeling and requires advanced imaging selection criteria
Contraindications Related to Time
Treatment is contraindicated (Class III: No Benefit) when 1:
- Time of symptom onset is unclear/unwitnessed AND time last known well is >3 or 4.5 hours
- Wake-up stroke with time last known well >3 or 4.5 hours (unless using advanced imaging protocols per newer research)
Common Pitfalls to Avoid
- Do not delay treatment to obtain additional history - if the patient was last known well within the time window, proceed
- Do not exclude patients based on outdated ECASS-III criteria (age >80, diabetes + prior stroke) when treating in the 3-4.5 hour window - these exclusions are not evidence-based 1
- Do not confuse "symptom onset" with "arrival time" - the clock starts when symptoms began or patient was last known well
- Do not use reduced-dose alteplase (0.6 mg/kg) - it is inferior to standard dosing 1, 4
Dosing Algorithm
Standard dose: 0.9 mg/kg (maximum 90 mg) 1:
- Give 10% as IV bolus over 1 minute
- Infuse remaining 90% over 60 minutes
This dosing applies to both the 0-3 hour and 3-4.5 hour windows. Lower doses have not shown equivalent efficacy 1.